Table 1.

ESGO–ESP–ESTRO prognostic groups of risk modified and rearranged from Crosbie et al. [55]. Non-E.C = Non E.C. carcinoma: serous, clear cell, carcinosarcoma, mixed, undifferentiated carcinoma. E.C. = E.C. carcinoma. LVSI = lymphovascular space invasion. NSMP = non-specific molecular pattern. St. = Stage.

	Molecular Classification				Molecular Classification
	Known				Unknown
	Pole-Mutant	Mmr-Deficient	NSMP	P53 Abnormal
Low risk	St. I-II, no residual disease	St. IA, E.C Low-grade, negative/focal LVSI			St. IA, E.C., low-grade, with negative
					or focal LVSI
Intermediate risk		St. IB E.C Low-grade with negative/focal LVSI		St. IA without myometrial invasion	St. IB, E.C. low-grade, negative or focal LVSI
		St. IA E.C., high-grade with			St. IA, E.C. high-grade, negative or focal LVSI
		negative/focal LVSI			St. IA non-E.C. without myometrial invasion
		St. IA non-E.C., without myometrial invasion
High-intermediate risk		St. I E.C., with substantial LVSI, regardless of grade or depth		St. I-IVA with myometrial invasion and no residual disease	St. I E.C. with substantial LVSI, regardless of grade or depth of invasion
		of invasion			St. IB, E.C. high-grade, regardless of LVSI
		St. IB high-grade E.C. with any LVSI			St. II E.C.
		St. II EC
High risk		St. III-IVA E.C., with no residual disease		St. I–IVA, with	St. III–IVA E.C. with no residual disease
		St. I-IVA non E.C. with no myometrial invasion and no residual disease		myometrial invasion and no residual disease	St. I–IVA non-E.C with myometrial invasion and no residual disease
Advanced/metastatic	St. II-IVA with residual disease				St. II–IVA with residual disease
	St. IV B				St. IVB